Novel Cyclic Pentadepsipeptide Derivative and Fusarium Strain Producing The Same

Abstract

Disclosed is a Fusarium strain producing novel cyclic pentadepsipeptides which are of excellent multidrug resistance-reversing activity and inhibitory activity against cancer cells. Also, novel cyclic pentadepsipeptides are provided as active ingredients of the compositions useful in the treatment of cancer and diseases associated with multidrug resistance.

1 . A  Fusarium  strain, producing a cyclic pentadepsipeptide, represented by Chemical Formula 1 or 2: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The  Fusarium  strain according to  claim 1 , belonging to  Fusarium solani.    
     
     
         3 . The  Fusarium  strain according to  claim 2 , being  Fusarium solani  KCCM90040 [Accession No. KCCM10881P]. 
     
     
         4 . A method of producing the cyclic pentadepsipeptide of Chemical Formula 1 or 2 of  claim 1  by culturing the strain of one of  claims 1  to  3 . 
     
     
         5 . The method according to  claim 4 , wherein the strain is cultured on a cereal substance. 
     
     
         6 . The method according to  claim 5 , wherein the cereal substance is rice. 
     
     
         7 . The method according to  claim 5 , wherein the strain is cultured at 20˜30° C. and 20˜50 RH % for 10˜20 days. 
     
     
         8 . A cyclic pentadepsipeptide, represented by the following Chemical Formula 1: 
       
         
           
           
               
               
           
         
       
     
     
         9 . A cyclic pentadepsipeptide, represented by the following Chemical Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         10 . A pharmaceutical composition for reversing multidrug resistance, comprising as an active ingredient at least one selected from a group consisting of the cyclic pentadepsipeptides of the following Chemical Formulas 1 and 2 and pharmaceutically acceptable salts thereof. 
       
         
           
           
               
               
           
         
       
     
     
         11 . The pharmaceutical composition according to  claim 10 , wherein the multidrug resistance comes from tumor cells. 
     
     
         12 . A pharmaceutical composition for treatment of cancer, comprising as an active ingredient at least one selected from a group consisting of the cyclic pentadepsipeptides of the following Chemical Formulas 1 and 2 and pharmaceutically acceptable salts thereof: